XNAS
MDGL
Market cap11bUSD
Oct 08, Last price
476.91USD
1D
-2.22%
1Q
-11.14%
Jan 2017
3,100.74%
IPO
41.20%
Name
Madrigal Pharmaceuticals Inc
Chart & performance
P/E
—
P/S
11.50
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.75%
Rev. gr., 5y
%
Revenues
958m
+432.05%
Net income
-288m
L-38.12%
CFO
-190m
L-58.39%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Key people
Bill Sibold
President, Chief Executive Officer, Director · since 2023
Chief Financial Officer, Executive Vice President, Principal Financial Officer · since 2026
Carole Huntsman
Executive Vice President, Chief Commercial Officer · since 2023
Shannon Kelley
Executive Vice President, Chief Legal Counsel · since 2024
David Soergel
Executive Vice President, Chief Medical Officer · since 2025
Rita Thakkar
Senior Vice President, Chief Accounting Officer, Principal Accounting Officer · since 2026
Director · since 2023
Director · since 2025
Independent Chairman of the Board · since 2023
Independent Director · since 2016
Raymond Cheong
Independent Director · since 2023
James Daly
Independent Director · since 2019
Jacqualyn Fouse
Independent Director · since 2025
Independent Director · since 2016
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
500 Office Center Drive
Suite 400
Washington, PA 19034
US
Suite 400
Washington, PA 19034
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||